First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study
Frontiers of Medicine · 2024-12 · 18 (6) · 1026-1034
DOI: 10.1007/s11684-024-1083-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Frontiers of Medicine, online erschienen am 06.11.2024. Verfasst von Jing Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynaecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
- Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
- Department of Gynecological Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 211166, China.
- Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
- Department of Gynecological Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 215311, China.
Zitieren
APA
Li, J., Chen, Y., He, M., Chen, X., Wen, H., Kang, Y., Liu, K., Lou, G., Wang, X., Wen, Q., Wang, L., & Lin, Z. (2024). First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study. Frontiers of Medicine, 18(6), 1026-1034. https://doi.org/10.1007/s11684-024-1083-5
Vancouver
Li J, Chen Y, He M, Chen X, Wen H, Kang Y, et al. First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study. Frontiers of Medicine. 2024;18(6):1026-1034. doi:10.1007/s11684-024-1083-5
BibTeX
@article{Li2024,
author = {Li, Jing and Chen, Youguo and He, Mian and Chen, Xiaoxiang and Wen, Hao and Kang, Yu and Liu, Kaijiang and Lou, Ge and Wang, Xipeng and Wen, Qinglian and Wang, Li and Lin, Zhongqiu},
title = {First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study},
journal = {Frontiers of Medicine},
year = {2024},
volume = {18},
number = {6},
pages = {1026--1034},
doi = {10.1007/s11684-024-1083-5}
}
EUVIMED